These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 17606739)

  • 1. Obesity and treatment of prostate cancer: what is the right dose of Lupron Depot?
    Agarwal N; Fletcher D; Ward J
    Clin Cancer Res; 2007 Jul; 13(13):4027. PubMed ID: 17606739
    [No Abstract]   [Full Text] [Related]  

  • 2. What should I know about Lupron Depot for treating prostate cancer?
    Johns Hopkins Med Lett Health After 50; 2012 Jan; 23(11):7. PubMed ID: 22396997
    [No Abstract]   [Full Text] [Related]  

  • 3. The effect of body mass index on PSA levels and the development, screening and treatment of prostate cancer.
    Skolarus TA; Wolin KY; Grubb RL
    Nat Clin Pract Urol; 2007 Nov; 4(11):605-14. PubMed ID: 17982437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of prostatic cancer with TAP-144-SR, a depot preparation of LH-RH agonist (leuprolide).
    Isurugi K; Niijima T; Akaza H; Aso Y; Koiso K; Fuse M; Okada K; Usami M; Ohashi T; Ueda T;
    J Chemother; 1989 Jul; 1(4 Suppl):1237-41. PubMed ID: 16312848
    [No Abstract]   [Full Text] [Related]  

  • 5. Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe.
    Tunn UW; Wiedey K
    Prostate Cancer Prostatic Dis; 2009; 12(1):83-7. PubMed ID: 19030021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy.
    Bañez LL; Sun L; Trock BJ; Han M; Partin AW; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Moul JW; Freedland SJ
    J Urol; 2009 Aug; 182(2):491-6; discussion 496-8. PubMed ID: 19524974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Male breast cancer during treatment with leuprolide for prostate cancer.
    Yacoub J; Richardson C; Farmer M; Lee WR; Clark PE; Hurt G; Levine EA
    Clin Adv Hematol Oncol; 2007 Jul; 5(7):555-6; discussion 556-7. PubMed ID: 17679929
    [No Abstract]   [Full Text] [Related]  

  • 8. [Galenic innovation: Enantone monthly depot preparations].
    Hübner R
    Urologe A; 1991 May; 30(3 Suppl):7-8. PubMed ID: 1746074
    [No Abstract]   [Full Text] [Related]  

  • 9. Performance and functional outcome of endoscopic extraperitoneal radical prostatectomy in relation to obesity: an assessment of 500 patients.
    Liatsikos E; Mühlstädt S; Kallidonis P; Rabenalt R; Do M; Burchardt M; Herrmann TR; Stolzenburg JU
    BJU Int; 2008 Sep; 102(6):718-22. PubMed ID: 18422768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
    Freedland SJ; Sun L; Kane CJ; Presti JC; Terris MK; Amling CL; Moul JW; Aronson WJ
    BJU Int; 2008 Sep; 102(8):969-74. PubMed ID: 18691175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic.
    Price MM; Hamilton RJ; Robertson CN; Butts MC; Freedland SJ
    Urology; 2008 May; 71(5):787-91. PubMed ID: 18267334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obesity and prostate cancer: an ambiguous relationship.
    Augustin H
    Eur J Cancer; 2007 May; 43(7):1114-6. PubMed ID: 17400442
    [No Abstract]   [Full Text] [Related]  

  • 13. Eligard. Tiny implant fights prostate cancer.
    Nursing; 2002 May; 32(5):18. PubMed ID: 12035639
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy over time of LHRH analogs in the treatment of PCa--a prospective analysis using serum testosterone to determine dosing intervals.
    Greil S; Robinson EA; Singal B; Kleer E
    Urology; 2009 Mar; 73(3):631-4. PubMed ID: 19110301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme.
    Pruthi RS; Swords K; Schultz H; Carson CC; Wallen EM
    J Urol; 2009 Feb; 181(2):574-7; discussion 578. PubMed ID: 19084847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
    Galvão DA; Spry NA; Taaffe DR; Newton RU; Stanley J; Shannon T; Rowling C; Prince R
    BJU Int; 2008 Jul; 102(1):44-7. PubMed ID: 18336606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leuprorelin, triptorelin: new indications. Locally advanced prostate cancer: minimally assessed me-toos.
    Prescrire Int; 2007 Dec; 16(92):243. PubMed ID: 18092407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prevalence of erectile dysfunction among Brazilian men screened for prostate cancer.
    Paranhos M; Antunes A; Andrade E; Freire G; Srougi M
    BJU Int; 2009 Oct; 104(8):1130-3. PubMed ID: 19426190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
    Culp S; Porter M
    BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.